Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides a source of calories and hydration; sodium chloride 0.45% provides electrolytes and maintains osmotic balance. Dextrose is metabolized to carbon dioxide and water, yielding energy. Sodium chloride dissociates to maintain extracellular fluid volume and osmolality.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Fluid and electrolyte replacement,Treatment of dehydration,Maintenance of hydration and caloric supply in patients unable to take oral fluids,Diluent for compatible medications
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous administration; typical adult dose is 1000-2000 m L over 24 hours, rate adjusted based on patient's fluid and electrolyte status. Maximum infusion rate is 1000 m L per hour.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Dextrose: not applicable as it is rapidly metabolized; the half-life of infused glucose is approximately 1.5-2 hours in healthy individuals, but prolonged in conditions like diabetes. Sodium: biological half-life is 10-20 hours, depending on fluid balance and renal function.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose undergoes glycolysis and subsequent oxidation via the citric acid cycle. Sodium chloride is not metabolized; it is excreted unchanged by the kidneys.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion of intact dextrose under normal conditions. Sodium and chloride are primarily excreted renally; sodium excretion is regulated by glomerular filtration and tubular reabsorption, while chloride follows sodium. In patients with normal renal function, >90% of infused sodium and chloride are excreted in urine within 24-48 hours.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: negligible binding to plasma proteins. Sodium: minimal binding (approx. 0-10%) to albumin and other proteins. Chloride: not significantly protein bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: distributes into total body water, approximately 0.55-0.65 L/kg (based on 60% of body weight as water in adults). Sodium: distributes into extracellular fluid, approximately 0.20-0.25 L/kg. Chloride: similar to sodium, extracellular fluid, approximately 0.20 L/kg.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% for all components.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
For GFR < 10 m L/min: reduce to 50% of standard dose or avoid due to risk of volume overload and hypernatremia; monitor closely for signs of fluid overload and electrolyte disturbances.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Not required: no dose adjustment needed for hepatic impairment.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous; dose based on daily maintenance fluid requirements: 0-10 kg: 100 m L/kg/day; 10-20 kg: 1000 m L + 50 m L/kg for each kg over 10; >20 kg: 1500 m L + 20 m L/kg for each kg over 20. Infusion rate adjusted to patient's clinical status.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use with caution: lower initial doses and slower infusion rates recommended to avoid fluid overload; monitor renal function and electrolyte balance.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
Use with caution in patients with congestive heart failure, renal impairment, or hyperglycemia,Monitor serum glucose, electrolytes, and fluid status,Risk of hyperglycemia and hyperosmolar syndrome in patients with diabetes mellitus or stress-induced insulin resistance,Not for use in patients with intracranial or intraspinal hemorrhage or in patients who are comatose with hyperglycemia
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperglycemia,Hypersensitivity to any component,Severe electrolyte abnormalities (e.g., hypernatremia),Patients with known allergies to corn or corn products (dextrose derived from corn)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid excessive intake of high-sodium foods such as processed snacks, canned soups, and fast foods to prevent exacerbation of sodium overload. No specific food interactions with dextrose; however, diabetic patients should monitor carbohydrate intake and adjust insulin accordingly. Alcohol may impair glucose metabolism and enhance hypoglycemia risk; avoid or limit consumption.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No known teratogenic risk. Dextrose and sodium chloride are physiologic substances. In trimester 1, no increased risk of major malformations. In trimesters 2 and 3, use is safe when indicated for maternal hydration or electrolyte balance; avoid excessive dextrose causing maternal hyperglycemia which can lead to fetal hyperinsulinism and neonatal hypoglycemia.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Excreted into breast milk in small amounts; M/P ratio not clinically relevant. Dextrose and sodium chloride are normal milk components. Considered compatible with breastfeeding; monitor infant for signs of electrolyte imbalance if high doses administered to mother.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No dose adjustment required for dextrose 5% and sodium chloride 0.45% in pregnancy. However, pregnant women have increased plasma volume; consider monitoring for fluid overload in conditions like preeclampsia. Insulin resistance may require glucose monitoring if large volumes are infused.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This isotonic solution (D5 0.45% Na Cl) provides 170 kcal/L as dextrose and 77 m Eq/L sodium, 77 m Eq/L chloride. Use cautiously in patients with hyponatremia or sodium retention (heart failure, cirrhosis, renal impairment). Monitor serum glucose in diabetic patients; may cause hyperglycemia. Not suitable for resuscitation due to low sodium content. Avoid in patients with known allergy to corn-derived dextrose.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any shortness of breath, swelling in legs, or rapid weight gain, as these may indicate fluid overload.,Inform your healthcare provider if you have diabetes, as this solution contains sugar and may affect blood glucose levels.,Tell your doctor if you have a history of kidney problems, heart failure, or high blood pressure.,Do not consume extra salt or salty foods without consulting your doctor.,Notify your nurse immediately if you experience pain, redness, or swelling at the infusion site.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.45% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is a Electrolyte that works by Dextrose 5% provides a source of calories and hydration; sodium chloride 0.45% provides electrolytes and maintains osmotic balance. Dextrose is metabolized to carbon dioxide and water, yielding energy. Sodium chloride dissociates to maintain extracellular fluid volume and osmolality.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.45% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is: Intravenous administration; typical adult dose is 1000-2000 m L over 24 hours, rate adjusted based on patient's fluid and electrolyte status. Maximum infusion rate is 1000 m L per hour.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.45% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is classified as Category A/B. No known teratogenic risk. Dextrose and sodium chloride are physiologic substances. In trimester 1, no increased risk of major malformations. In trimesters 2 and 3, use is safe whe. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.